Florine A Berger1, Nico Monadian2, Natasja M S de Groot3, Bart Santbergen4, Heleen van der Sijs1, Matthijs L Becker5, Annoek E C Broers6, Teun van Gelder1, Patricia M L A van den Bemt1. 1. Department of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands. 2. Erasmus University, Rotterdam, The Netherlands. 3. Department of Cardiology, Erasmus University Medical Centre, Rotterdam, The Netherlands. 4. Department of Internal Medicine, IJsselland Hospital, Capelle a/d Ijssel, The Netherlands. 5. Pharmacy Foundation of Haarlem Hospitals, Haarlem, The Netherlands. 6. Department of Haematology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Abstract
AIM(S): Ciprofloxacin and fluconazole combination therapy is frequently used as prophylaxis for, and treatment of, infections in patients with haematological malignancies. However, both drugs are known to prolong the heart rate-corrected QT (QTc) interval, which is a serious risk factor for torsade de pointes (TdP). Therefore, the aim of the current study was to assess the prevalence of QTc prolongation during ciprofloxacin and fluconazole use. The secondary objective was to determine associated risk factors of QTc prolongation in these patients. METHODS: A prospective observational study was performed in patients admitted to the Erasmus University Medical Centre and treated with ciprofloxacin and fluconazole. A 12-lead electrocardiogram (ECG) was recorded at the estimated time to peak concentration (Tmax ) for the last added drug. The main outcome was the proportion of patients with QTc prolongation during treatment. Data on the following potential risk factors were collected: patient characteristics, serum electrolyte levels, dosage of ciprofloxacin and fluconazole, renal and liver function and concomitant use of other QTc-prolonging drugs and cytochrome P450 3A4 inhibitors. RESULTS: A total of 170 patients were included, of whom 149 (87.6%) were treated for haematological malignancies. The prevalence of QTc prolongation was 4.7%. No risk factors were found to be associated with QTc prolongation. The QTc interval increased by 10.7 ms [95% confidence interval (CI) 7.2, 14.1 ms] during ciprofloxacin and fluconazole combination therapy. CONCLUSION: The prevalence of QTc prolongation in patients using ciprofloxacin and fluconazole is low compared with the prevalence in the general population, which varies from 5% to 11%. In addition, no risk factors were found. Given the low prevalence, routine ECG monitoring in patients on this therapy should be reconsidered.
AIM(S): Ciprofloxacin and fluconazole combination therapy is frequently used as prophylaxis for, and treatment of, infections in patients with haematological malignancies. However, both drugs are known to prolong the heart rate-corrected QT (QTc) interval, which is a serious risk factor for torsade de pointes (TdP). Therefore, the aim of the current study was to assess the prevalence of QTc prolongation during ciprofloxacin and fluconazole use. The secondary objective was to determine associated risk factors of QTc prolongation in these patients. METHODS: A prospective observational study was performed in patients admitted to the Erasmus University Medical Centre and treated with ciprofloxacin and fluconazole. A 12-lead electrocardiogram (ECG) was recorded at the estimated time to peak concentration (Tmax ) for the last added drug. The main outcome was the proportion of patients with QTc prolongation during treatment. Data on the following potential risk factors were collected: patient characteristics, serum electrolyte levels, dosage of ciprofloxacin and fluconazole, renal and liver function and concomitant use of other QTc-prolonging drugs and cytochrome P450 3A4 inhibitors. RESULTS: A total of 170 patients were included, of whom 149 (87.6%) were treated for haematological malignancies. The prevalence of QTc prolongation was 4.7%. No risk factors were found to be associated with QTc prolongation. The QTc interval increased by 10.7 ms [95% confidence interval (CI) 7.2, 14.1 ms] during ciprofloxacin and fluconazole combination therapy. CONCLUSION: The prevalence of QTc prolongation in patients using ciprofloxacin and fluconazole is low compared with the prevalence in the general population, which varies from 5% to 11%. In addition, no risk factors were found. Given the low prevalence, routine ECG monitoring in patients on this therapy should be reconsidered.
Authors: Andreas D Meid; Anna von Medem; Dirk Heider; Jürgen-Bernhard Adler; Christian Günster; Hanna M Seidling; Renate Quinzler; Hans-Helmut König; Walter E Haefeli Journal: Drug Saf Date: 2017-02 Impact factor: 5.606
Authors: Barbara J Drew; Michael J Ackerman; Marjorie Funk; W Brian Gibler; Paul Kligfield; Venu Menon; George J Philippides; Dan M Roden; Wojciech Zareba Journal: Circulation Date: 2010-02-08 Impact factor: 29.690
Authors: Sabine M J M Straus; Miriam C J M Sturkenboom; Gysèle S Bleumink; Jeanne P Dieleman; Johan van der Lei; Pieter A de Graeff; Jan Herre Kingma; Bruno H Ch Stricker Journal: Eur Heart J Date: 2005-05-11 Impact factor: 29.983
Authors: J L Goodman; D J Winston; R A Greenfield; P H Chandrasekar; B Fox; H Kaizer; R K Shadduck; T C Shea; P Stiff; D J Friedman Journal: N Engl J Med Date: 1992-03-26 Impact factor: 91.245
Authors: Florine A Berger; Nico Monadian; Natasja M S de Groot; Bart Santbergen; Heleen van der Sijs; Matthijs L Becker; Annoek E C Broers; Teun van Gelder; Patricia M L A van den Bemt Journal: Br J Clin Pharmacol Date: 2017-12-06 Impact factor: 4.335
Authors: Yuanyuan Wang; Muh Akbar Bahar; Anouk M E Jansen; Janwillem W H Kocks; Jan-Willem C Alffenaar; Eelko Hak; Bob Wilffert; Sander D Borgsteede Journal: J Antimicrob Chemother Date: 2019-10-01 Impact factor: 5.790
Authors: Koen G A M Hussaarts; Florine A Berger; Lisette Binkhorst; Esther Oomen-de Hoop; Roelof W F van Leeuwen; Robbert J van Alphen; Daniëlle Mathijssen-van Stein; Natasja M S de Groot; Ron H J Mathijssen; Teun van Gelder Journal: Pharm Res Date: 2019-12-16 Impact factor: 4.200
Authors: Pawel Miotla; Pawel Olejniczak; Konrad Futyma; Andrzej Wrobel; Michal Tomaszewski; Michal Bogusiewicz; Sara Wawrysiuk; Ewa Markut-Miotla; Tomasz Rechberger Journal: J Clin Med Date: 2018-09-09 Impact factor: 4.241
Authors: Florine A Berger; Willem van Weteringen; Heleen van der Sijs; Nicole G M Hunfeld; Jeroen J H Bunge; Natasja M S de Groot; Patricia M L A van den Bemt; Teun van Gelder Journal: Pharmacol Res Perspect Date: 2021-12